Antisaccade task reflects cortical involvement in mild cognitive impairment

Neurology

Volumn 81, Issue 14, 2013, Pages 1235-1243

  Heuer, Hilary W ^a   Mirsky, Jacob B ^a   Kong, Erwin L ^a   Dickerson, Bradford C ^b   Miller, Bruce L ^a   Kramer, Joel H ^a   Boxer, Adam L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ANTISACCADIC EYE MOVEMENT; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DISEASE SEVERITY; EXECUTIVE FUNCTION; EYE MOVEMENT CONTROL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SACCADIC EYE MOVEMENT; TASK PERFORMANCE;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; CEREBRAL CORTEX; EXECUTIVE FUNCTION; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; SACCADES; SEVERITY OF ILLNESS INDEX;

EID: 84888337094     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a6cbfe     Document Type: Article

References (31)

1. Grady CL. The cognitive neuroscience of aging. Nat Rev Neurosci 2012;13:491-505.
2. Hellmuth J, Mirsky J, Heuer HW, et al. Multi-center validation of a bedside anti-saccade task as a measure of executive function. Neurology 2012;78:1824-1831.
3. Reuter B, Rakusan L, Kathmanna N. Poor antisaccade performance in schizophrenia: An inhibition deficit? Psychiatry Res 2005;135:1-10. (Pubitemid 40733534)
4. Hutton SB, Huddy V, Barnes TR, et al. The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia. Biol Psychiatry 2004;56:553-559. (Pubitemid 39336402)
5. Boxer AL, Garbutt S, Rankin KP, et al. Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration. J Neurosci 2006;26:6354-6363.
6. Garbutt S, Matlin A, Hellmuth J, et al. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain 2008;131(pt 5):1268-1281.
7. Munoz DP, Everling S. Look away: The anti-saccade task and the voluntary control of eye movement. Nat Rev Neurosci 2004;5:218-228. (Pubitemid 38252478)
8. O'Driscoll GA, Alpert NM, Matthysse SW, Levy DL, Rauch SL, Holzman PS. Functional neuroanatomy of antisaccade eye movements investigated with positron emission tomography. Proc Natl Acad Sci USA 1995;92:925-929.
9. Ettinger U, Kumari V, Zachariah E, et al. Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology 2003;28:2199-2208. (Pubitemid 37468188)
10. Mirsky J, Heuer HW, Jafari A, et al. Anti-saccade performance predicts executive function and brain structure in normal elders. Cogn Behav Neurol 2011;24:50-58.
11. Blekher T, Johnson SA, Marshall J, et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology 2006;67:394-399. (Pubitemid 44214959)
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308. (Pubitemid 29120227)
13. Kao AW, Eisenhut RJ, Martens LH, et al. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc Natl Acad Sci USA 2011;108:4441-4446.
14. Blacker D, Lee H, Muzikansky A, et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 2007;64:862-871. (Pubitemid 46919842)
15. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloidpositive individuals. Cereb Cortex 2009;19:497-510.
16. Agosta F, Vossel KA, Miller BL, et al. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci USA 2009;106:2018-2022.
17. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
18. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414. (Pubitemid 23346995)
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ARDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
20. Kramer JH, Jurik J, Sha SJ, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 2003;16:211-218. (Pubitemid 37517826)
21. Delis DC, Kaplan EB, Kramer JH. The Delis-Kaplan Executive Function System. San Antonio: The Psychological Corporation; 2001.
22. Kaplan E, Goodglass H, Wintraub S. The Boston Naming Test. Philadelphia: Lea & Febiger; 1983.
23. Warrington EK, James M. The Visual Object and Space Perception Battery. Bury St Edmunds: Thames Valley Test Company; 1991.
24. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329. (Pubitemid 12117513)
25. Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD. ADCS Prevention Instrument Project: Assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord 2006;20(suppl 3):S152-S169. (Pubitemid 44900699)
26. Shafiq-Antonacci R, Maruff P, Masters C, Currie J. Spectrum of saccade system function in Alzheimer disease. Arch Neurol 2003;60:1272-1278. (Pubitemid 37099635)
27. Dickerson BC, Wolk DA. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011;82:45-51.
28. Dickerson BC, Wolk DA. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012;78:84-90.
29. Arnsten AF, Wang MJ, Paspalas CD. Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron 2012;76:223-239.
30. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One 2012;7: e29630.
31. Roffman JL, Nitenson AZ, Agam Y, et al. A hypomethylating variant of MTHFR, 677C.T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS One 2011;6:e25253.